Matthias S Matter1,2, Jens U Marquardt1,3, Jesper B Andersen1,4, Cristina Quintavalle2, Nikolay Korokhov1, Jim K Stauffer5, Kosuke Kaji1, Thomas Decaens1, Luca Quagliata2, Fathi Elloumi6, Tanya Hoang2, Alfredo Molinolo7, Elizabeth A Conner1, Achim Weber8, Mathias Heikenwalder9,10, Valentina M Factor1, Snorri S Thorgeirsson1. 1. Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. 2. Institute of Pathology, University Hospital of Basel, Basel, Switzerland. 3. Department of Medicine I, Johannes Gutenberg University, Mainz, Germany. 4. Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark. 5. Cancer and Inflammation Program, National Cancer Institute-Frederick, Frederick, MD. 6. National Cancer Institute, CCR at Leidos Inc., National Institutes of Health, Bethesda, MD. 7. Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD. 8. Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland. 9. Institute of Virology, Technische Universität München/Helmholtz Zentrum München, Munich, Germany. 10. Division of Chronic Inflammation and Cancer, German Cancer Research Center, Heidelberg, Germany.
Abstract
UNLABELLED: The majority of hepatocellular carcinoma develops in the background of chronic liver inflammation caused by viral hepatitis and alcoholic or nonalcoholic steatohepatitis. However, the impact of different types of chronic inflammatory microenvironments on the phenotypes of tumors generated by distinct oncogenes is largely unresolved. To address this issue, we generated murine liver tumors by constitutively active AKT-1 (AKT) and β-catenin (CAT), followed by induction of chronic liver inflammation by 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) and carbon tetrachloride. Also, the impact of DDC-induced chronic liver inflammation was compared between two liver tumor models using a combination of AKT-CAT or AKT-NRAS(G12V) . Treatment with DDC and carbon tetrachloride significantly facilitated the adenoma-to-carcinoma conversion and accelerated the growth of AKT-CAT tumors. Furthermore, DDC treatment altered the morphology of AKT-CAT tumors and caused loss of lipid droplets. Transcriptome analysis of AKT-CAT tumors revealed that cellular growth and proliferation were mainly affected by chronic inflammation and caused up-regulation of Cxcl16, Galectin-3, and Nedd9, among others. Integration with transcriptome profiles from human hepatocellular carcinomas further demonstrated that AKT-CAT tumors generated in the context of chronic liver inflammation showed enrichment of poor prognosis gene sets or decrease of good prognosis gene sets. In contrast, DDC had a more subtle effect on AKT-NRAS(G12V) tumors and primarily enhanced already existent tumor characteristics as supported by transcriptome analysis. However, it also reduced lipid droplets in AKT-NRAS(G12V) tumors. CONCLUSION: Our study suggests that liver tumor phenotype is defined by a combination of driving oncogenes but also the nature of chronic liver inflammation. (Hepatology 2016;63:1888-1899).
UNLABELLED: The majority of hepatocellular carcinoma develops in the background of chronic liver inflammation caused by viral hepatitis and alcoholic or nonalcoholic steatohepatitis. However, the impact of different types of chronic inflammatory microenvironments on the phenotypes of tumors generated by distinct oncogenes is largely unresolved. To address this issue, we generated murineliver tumors by constitutively active AKT-1 (AKT) and β-catenin (CAT), followed by induction of chronic liver inflammation by 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) and carbon tetrachloride. Also, the impact of DDC-induced chronic liver inflammation was compared between two liver tumor models using a combination of AKT-CAT or AKT-NRAS(G12V) . Treatment with DDC and carbon tetrachloride significantly facilitated the adenoma-to-carcinoma conversion and accelerated the growth of AKT-CAT tumors. Furthermore, DDC treatment altered the morphology of AKT-CAT tumors and caused loss of lipid droplets. Transcriptome analysis of AKT-CAT tumors revealed that cellular growth and proliferation were mainly affected by chronic inflammation and caused up-regulation of Cxcl16, Galectin-3, and Nedd9, among others. Integration with transcriptome profiles from humanhepatocellular carcinomas further demonstrated that AKT-CAT tumors generated in the context of chronic liver inflammation showed enrichment of poor prognosis gene sets or decrease of good prognosis gene sets. In contrast, DDC had a more subtle effect on AKT-NRAS(G12V) tumors and primarily enhanced already existent tumor characteristics as supported by transcriptome analysis. However, it also reduced lipid droplets in AKT-NRAS(G12V) tumors. CONCLUSION: Our study suggests that liver tumor phenotype is defined by a combination of driving oncogenes but also the nature of chronic liver inflammation. (Hepatology 2016;63:1888-1899).
Authors: Bob Thoolen; Robert R Maronpot; Takanori Harada; Abraham Nyska; Colin Rousseaux; Thomas Nolte; David E Malarkey; Wolfgang Kaufmann; Karin Küttler; Ulrich Deschl; Dai Nakae; Richard Gregson; Michael P Vinlove; Amy E Brix; Bhanu Singh; Fiorella Belpoggi; Jerrold M Ward Journal: Toxicol Pathol Date: 2010-12 Impact factor: 1.902
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Takeki Uehara; Garrett R Ainslie; Kristi Kutanzi; Igor P Pogribny; Levan Muskhelishvili; Takeshi Izawa; Jyoji Yamate; Oksana Kosyk; Svitlana Shymonyak; Blair U Bradford; Gary A Boorman; Ramon Bataller; Ivan Rusyn Journal: Toxicol Sci Date: 2013-01-03 Impact factor: 4.849
Authors: Yujin Hoshida; Augusto Villanueva; Masahiro Kobayashi; Judit Peix; Derek Y Chiang; Amy Camargo; Supriya Gupta; Jamie Moore; Matthew J Wrobel; Jim Lerner; Michael Reich; Jennifer A Chan; Jonathan N Glickman; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Maria G Daidone; Sasan Roayaie; Myron Schwartz; Swan Thung; Helga B Salvesen; Stacey Gabriel; Vincenzo Mazzaferro; Jordi Bruix; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub Journal: N Engl J Med Date: 2008-10-15 Impact factor: 91.245
Authors: Edward R Kastenhuber; Gadi Lalazar; Shauna L Houlihan; Darjus F Tschaharganeh; Timour Baslan; Chi-Chao Chen; David Requena; Sha Tian; Benedikt Bosbach; John E Wilkinson; Sanford M Simon; Scott W Lowe Journal: Proc Natl Acad Sci U S A Date: 2017-11-21 Impact factor: 11.205
Authors: Carolin Czauderna; Mayrel Palestino-Dominguez; Darko Castven; Diana Becker; Luis Zanon-Rodriguez; Jovana Hajduk; Friederike L Mahn; Monika Herr; Dennis Strand; Susanne Strand; Stefanie Heilmann-Heimbach; Luis E Gomez-Quiroz; Marcus A Wörns; Peter R Galle; Jens U Marquardt Journal: PLoS One Date: 2018-12-21 Impact factor: 3.240